Cellectis S.A. is a clinical-stage biopharmaceutical company specializing in allogeneic chimeric antigen receptor T-cell (CAR-T) therapies engineered with its proprietary TALEN® gene-editing technology. The company focuses on developing off-the-shelf cellular immunotherapies designed to target hematologic malignancies and solid tumors. By using donor-derived T cells, Cellectis aims to streamline manufacturing processes and deliver treatments more rapidly than traditional autologous approaches.
Founded in 1999 and headquartered in Paris, France, Cellectis has built a comprehensive research and development platform that integrates gene editing, cell line engineering, and process development. The company entered the Nasdaq market in 2015, marking a pivotal step in its growth strategy. Under the leadership of founder and CEO Dr. André Choulika, Cellectis has expanded its TALEN technology repertoire and established partnerships to enhance clinical translational capabilities.
Beyond its Paris headquarters, Cellectis maintains research sites in New York and operates GMP-compliant manufacturing facilities across Europe and the United States. Its global clinical pipeline includes multiple allogeneic CAR-T candidates targeting indications such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, and select solid tumors. Collaborative agreements with pharmaceutical companies and academic centers support the company’s efforts to explore novel targets and combination regimens.
Looking forward, Cellectis is advancing pivotal clinical trials for its lead candidates while investing in next-generation gene-editing solutions to improve safety profiles and therapeutic efficacy. With a growing footprint in major markets and a commitment to innovation, the company is strategically positioned to address unmet needs in oncology and drive the broader adoption of allogeneic cell therapies.
AI Generated. May Contain Errors.
Free CLLS Stock Alerts